Now showing items 1-7 of 7
Rolling out antiretrovirals in Africa: there are still challenges ahead
(Infectious Diseases Society of America, 2005-08)
In their article “Lessons Learned from Highly Active Antiretroviral Therapy in Africa,” Akileswaran et al.  review the effectiveness of HAART programs in Africa. They report positive health outcomes, including high ...
HIV immune reconstitution syndrome in sub-Saharan Africa
(Lippincott Williams & Wilkins, 2008)
Over the last 5 years, there has been remarkable progress in providing HAART to patients in developing countries. In sub-Saharan Africa alone, the number receiving antiretroviral therapy (ART) has more than doubled in ...
Adherence to antiretroviral therapy in HIV-positive adolescents in Uganda assessed by multiple methods a prospective cohort study
Background: The effectiveness of traditional adherence measurements used in adolescent populations isdifficult to assess. Antiretroviral (ARV) adherence research among adolescents living with HIV in resourceconstrained ...
Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy
Background. Cryptococcal meningitis (CM) is the proximate cause of death in 20%–30% of persons with acquired immunodeficiency syndrome in Africa. Methods. Two prospective, observational cohorts enrolled human immunodeficiency ...
Are the best antiretrovirals being used in Africa?
(Mediscript Limited, 2006)
Biomarkers of HIV immune reconstitution inflammatory syndrome
(Future Medicine, 2008)
Dysregulation of the immune system drives HIV pathogenesis. As we develop new ways to treat HIV and AIDS, we encounter new clinical ramifications of our treatment on regulatory components of the Immune system. HIV-associated ...
HIV Eosinophilic Folliculitis in Uganda
(American Medical Association (AMA), 2006)